email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
766 - 780
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma
$5.00
Available
Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor
$5.00
Available
Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer
$5.00
Available
GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug
$5.00
Available
Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal
$5.00
Available
Shanghai Zai Lab Raises Hong Kong Listing to Primary Status
$5.00
Available
Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug
$5.00
Available
Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers
$5.00
Available
Reistone Completes $100 Million A Round for Inflammatory Disease Drugs
$5.00
Available
Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million
$5.00
Available
Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal
$5.00
Available
InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors
$5.00
Available
OcuMension Approved to Launch Novel Uveitis Therapy in China
$5.00
Available
Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines
$5.00
Available
MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots
$5.00
Available